Search
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. … Anthralin has also been studied in the treatment of warts, showing promising results [A32307].
Tralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalUS in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the
Voretigene neparvovec
go.drugbank.com/drugs/DB13932ApprovedInvestigationalVoretigene Neparvovec-rzyl (VN-rzyl) is an adeno-associated virus vector-based gene therapy.[L1094] An adeno-associated virus is a small virus that infects humans and other primates. … [A31478] VN-rzyl was developed by Spark Therapeutics Inc. and FDA approved on December 19, 2017.[L1095]
Synonyms: VN-rzylPixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnAnother phase III trial, PIX-R, is now ongoing to clarify pixantrones place in therapy. It will compare pixantrone efficacy to that of gemcitabine. [2] … Based on this uncertainty, in 2009, the FDA ultimately rejected Cell Therapeutic's initial application for accelerated approval for pixantrone use in relapsed or refractory NHL.
Oxilofrine
go.drugbank.com/drugs/DB11610ApprovedOxilofrine is used in combination with [DB11609] as an antitussive. It is currently marketed in Canada by Valeant under the tradename Cophylac.
Bordetella pertussis pertactin antigen
go.drugbank.com/drugs/DB10789ApprovedInvestigationalBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis .
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Covaxis Injektionssuspension in einer FertigspritzeTeriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigational[A251395] Teriparatide is used in the treatment of osteoporosis in men and women.[L42590, L42595] … [A251395] First approved in the United States in November 2002 and in Europe in April 2003,[A251400] teriparatide makes the first approved drug in a new category of osteoporosis therapy called anabolic
Products: SONDELBAY (Teriparatide) 20 micrograms/ 80 microliters solution for injection in pre-filled pen, Teriparatid ratiopharm 20 Mikrogramm/80 Mikroliter Injektionslösung in einem vorgefüllten InjektorLenacapavir
go.drugbank.com/drugs/DB15673ApprovedInvestigational[L42995] On December 22, 2022, it was also approved by the FDA.[L44473] … HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens
Synonyms: N-((1S)-1-(3-(4-CHLORO-3-(METHANESULFONAMIDO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-(METHANESULFONYL)-3-METHYLBUT-1-YN-1-YL)PYRIDIN-2-YL)-2-(3,5- DIFLUOROPHENYL)ETHYL)-2-((3BS,4AR)-5,5-DIFLUORO, 1H-CYCLOPROPA(3,4)CYCLOPENTA(1,2-C)PYRAZOLE, N-((1S)-1-(3-(4-CHLORO-3-((METHYLSULFONYL)AMINO)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL-7-YL)-6-(3-METHYL-3-(METHYLSULFONYL)-1-BUTYN-1-YL)-2-PYRIDINYL)-2-(3,5-Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalThe treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. … Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC).
Phenoxyethanol
go.drugbank.com/drugs/DB11304ApprovedInvestigationalIt is produced by reacting phenol (EU) and ethylene oxide (EU) at a high temperature and pressure. This substance occurs naturally in green tea (EU) [L2621]. … According to the European Union Cosmetics Regulation (EC) n.1223/2009, phenoxyethanol is authorized as a preservative in cosmetic formulations at a maximum concentration of 1.0% [L2625].